尤瑞克林联合双抗血小板治疗进展性脑梗死的临床观察

Clinical observation of urinarykallid and dual antiplatelet therapy in progressive cerebral infarction

目的观察尤瑞克林联合双抗血小板治疗进展性脑梗死的临床效果。方法 124例进展性脑梗死患者随机分为观察组和对照组。两组均用阿司匹林联合氯吡格雷治疗2周,观察组加用尤瑞克林。观察治疗后2周的疗效、神经功能缺损程度和日常生活能力。结果观察组疗效、NIHSS评分、Barthel指数均优于对照组(P<0.01),而两组间不良反应发生率差异无统计学意义(P>0.05)。结论尤瑞克林联合双抗血小板治疗进展性脑梗死效果显著,可改善神经功能及日常生活能力。

Objective To observe the clinical effect of urinarykallid and dual antiplatelet therapy in progressive cerebral infarction （PCI）. Methods A total of 124 PCI patients were randomly divided into observation and control groups. Two groups were treated with aspirin and clopidogrel for 2 weeks, while observation group was added with urinarykallid. The therapeutic efficacy, neurological deficits and activities of daily living were compared between two groups at 2 weeks posttreatment. Results The therapeutic efficacy, NIHSS scores and Barthel indexes were better in observation group than in control group （P〈0.01）, but adverse reactions were comparable between two groups （P〉0.05）..Conclusion The combined urinarykallid and dual antiplatelet therapy is effective and improves the neurological function and activities of daily living in patients with PCI.